Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Voranigo (Vorasidenib) is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery, including biopsy, subtotal resection, or gross total resection.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Vorasidenib, an IDH inhibitor, has demonstrated significant efficacy in treating grade 2 gliomas in patients who have not previously undergone radiotherapy (RT) or chemotherapy (CT), suggesting it may be an effective treatment option for this population.
• No direct comparative effectiveness data is provided between vorasidenib and other treatment modalities such as surgery, RT, or CT within the same study.
• The studies do not detail differences in effectiveness among various population types or subgroups, limiting conclusions on subgroup-specific efficacy.
• There is no safety information available in the reviewed studies.
• The studies focus on adult patients with grade 2 gliomas, particularly oligodendrogliomas and astrocytomas with IDH mutations, and highlight the significant efficacy of IDH inhibitors like vorasidenib in these tumors not previously treated with RT or CT; no additional subgroup-specific findings are available.